Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1483 - A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)

Date

08 Oct 2016

Session

Poster Display

Presenters

Carolyn Krasner

Citation

Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374

Authors

C.N. Krasner1, R.J. Schilder2, W.E. Brady3, L.R. Duska4, D. O'Malley5, P.A. Disilvestro6, J. Li7, W. Downing7, A. Senderowicz7

Author affiliations

  • 1 Hematology/oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Medical Oncology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 3 Department Of Biostatistics And Bioinformatics, Roswell Park Cancer Institute, 14263-0001 - Buffalo/US
  • 4 Gynecologic Oncology, University of Virginia, 22903 - Charlottesville/US
  • 5 Obstetrics And Gynecology, The Ohio State University James Cancer Hospital, 43210 - Columbus/US
  • 6 Gynecologic Oncology, Women & Infants Hospital Warren Alpert Medical School of Brown Univ, 02905 - Providence/US
  • 7 Medical Affairs, Cerulean Pharma, Inc., 02451 - Waltham/US
More

Resources

Abstract 1483

Background

Cerulean Pharma, Inc. is developing CRLX101, an investigational NDC with a camptothecin payload. CRLX101 has been investigated in more than 350 pts as monotherapy or in combination with bevacizumab in pts with renal cell carcinoma (Keefe, ASCO 2015, abstract #4543) and platinum-refractory OC (Krasner, ASCO 2014, abstract #5581). Preclinical and early clinical data suggest synergy between taxanes and topoisomerase 1 inhibitors. We started a Phase 1b trial for this combination in pts with platinum-resistant OC.

Methods

Cohorts of 3 pts were accrued in this trial. Two dose levels of CRLX101 (every other week) in combination with weekly [wkly] paclitaxel 80 mg/m2 (3 wks on/1 wk off) were planned: dose level 1, CRLX101 12 mg/m2; dose level 2, CRLX101 15 mg/m2 . The primary objective was to determine the maximum tolerated dose of CRLX101 in combination with wkly paclitaxel. Secondary objectives included pharmacokinetics, safety, tolerability, and clinical activity.

Results

As of March 11, 2016, 9 pts have been enrolled and treated at dose levels 1 (n = 3) and 2 (n = 6); all pts were evaluable for safety and response. Median age was 61 years (range, 49–73); median number of previous regimens was 3 (range, 1–4). GOG score performance status was 0 (6 pts) or 1 (3 pts). No dose-limiting toxicities have been reported at either dose level, thus the RP2D is CRLX101 15 mg/m2 (every other week) and paclitaxel 80 mg/m2 (3 weeks on/1 week off). Treatment-related adverse events (AEs) included fatigue (6/9, 67%), neutrophil count decreased (4/9, 44%), nausea (4/9, 44%), vomiting, alopecia, headache, infusion-related reaction, and urinary tract infection (2/9, 22% for all). The only grade ≥3 treatment-related AE was neutropenia, which occurred in 2 pts (1 grade 3; 1 grade 4). Partial response and stable disease rates were 56% (5/9) and 11% (1/9), respectively. Moreover, CA125 responses (≥50% decline from baseline) were demonstrated in 33% (3/9) of pts. Two pts (at 15 mg/m2) are still receiving therapy.

Conclusions

CRLX101 given every other wk in combination with wkly paclitaxel has demonstrated early signs of antitumor activity and has been generally well tolerated to date in pts with platinum-resistant OC.

Clinical trial identification

NCT02389985

Legal entity responsible for the study

Cerulean Pharma, Inc.

Funding

Cerulean Pharma, Inc.

Disclosure

R.J. Schilder: reports personal fees from Millennium, Clovis, MedImmune and Merck Serrano. D. O'Malley: reports personal fees from Clovis, Janssen, AstraZeneca, Genentech/Roche, Eisai and Clovis. J. Li, W. Downing, A. Senderowicz: is an employee of Cerulean Pharma, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings